Efforts to Counteract Locally the Effects of Systemic Immunosupression: A Review on the Use of Imiquimod,a Topical Immunostimulator in Organ Transplant Recipients
Free accessEditorialFirst published online April, 2010
Efforts to Counteract Locally the Effects of Systemic Immunosupression: A Review on the Use of Imiquimod,a Topical Immunostimulator in Organ Transplant Recipients
The potent systemic immunosuppression therapy necessary to sustain a life-saving solid organ transplant is associated with an increased incidence of various infections including human papillomavirus infection and skin cancers in organ transplant recipients. Imiquimod, a topical agent that functions through local induction of a specific anti-viral or anti-tumor immune response, appears to be a promising therapeutic option that could potentially counteract in situ the effects of systemic immunosupression in this vulnerable group. Up-to-date studies using this local immune-response modifier in transplanted patients have yielded reassuring and encouraging results regarding its safety and efficacy in this population. However, in order to establish the use of imiquimod as a standard treatment option for organ transplant recipients, additional research and clinical trials are required.
TyringSConantMMariniM. Imiquimod; an international update on therapeutic uses in dermatology. Int J Dermatol2002; 41:810–16.
2.
KovachBTStaskoT. Use of topical immunomodulators in organ transplant recipients. Dermatol Ther2005; 18:19–27.
3.
JosephF. Buell, Thomas G. Gross, E. Steve Woodle. Malignancy after transplantation. Transplantation2005; 80(S):2.
4.
DantalJPohankaE. Nephrol. malignancies in renal transplantation: an unmet medical need. Dial Transplant2007; 22(S):4–10.
5.
RamsayHMFryerAAReeceSSmithAGHardenPN. Clinical risk factors associated with non-melanoma skin cancer in renal transplant recipients. Am J Kidney Dis2000; 36:167–76.
6.
EuvrardSKanitakisJClaudyA. Skin cancers after organ transplantation. N Engl J Med2003; 348:1681–91.
7.
GerliniGRomagnoliPPimpinelliN. Skin cancer and immunosuppression. Crit Rev Oncol/Hematol2005; 56:127–36.
8.
UlrichCSchmookTNindlIMeyerTSterryWStockflethE. Cutaneous precancers in organ transplant recipients: an old enemy in a new surrounding. Br J Dermatol2003; 149(S):40–2.
9.
Bouwes-BavinckJNHardieDRGreenA. The risk of skin cancer in renal transplant recipients in Queensland, Australia: a follow-up study. Transplantation1996; 61:715–21.
10.
HarteveltMMBavinckJNKootteAMMVermeerBJVandenbrouckeJP. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation1990; 49:506–9.
11.
MartinezJCOtleyCCStaskoT. Transplant-Skin Cancer Collaborative. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol2003; 139:301–6.
12.
BoydASStaskoTCameronGSRussellMKingLEJr. Histologic features of actinic keratoses in solid organ transplant recipients and healthy controls. J Am Acad Dermatol2001; 45:217–21.
13.
MendezJCPayaCV. Kaposi's sarcoma and transplantation. Herpes2000; 7:18–23.
14.
StalloneGSchenaAInfanteB. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med2005; 352:1317–23.
15.
SchmookTNindlIUlrichC. Viral warts in organ transplant recipients: new aspects in therapy. Br J Dermatol2003; 149(S):20–4.
16.
LeighIMGloverMT. Cutaneous warts and tumours in immunosuppressed patients. J R Soc Med1995; 88:61–2.
17.
BlessingKMcClarenKMBentonEC. Histopathology of skin lesions in renal allograft recipients: an assessment of viral features and dysplasia. Histopathology1989; 14:129–39.
18.
StockflethENindlISterryWUlrichCSchmookTMeyerT. Human papillomaviruses in transplant-associated skin cancers. Dermatol Surg2004; 30:604–9.
19.
StanleyMA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol2002; 27:571–7.
20.
GaspariAAMechanism of action and other potential roles of an immune response modifier. Cutis2007; 79(S):36–45.
21.
HemmiHKaishoTTakeuchiO. Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol2002; 3:196–200.
22.
IwasakiAMedzhitovR. Toll-like receptor control of the adaptive immune responses. Nat Immunol2004; 5:987–95.
23.
ThatcherTHLuzinaIFishelevichR, Tomai light induced loss of contact hypersensitivity MA, MillerRLGaspariAA. Topical imiquimod treatment prevents UV- and immune tolerance. J Invest Dermatol2006; 126:821–31.
24.
SuzukiHWangBShivjiGM. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol2000; 114:135–41.
25.
BurnsRPJrFerbelBTomaiMMillerRGaspariAA. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol2000; 94:13–23.
26.
SchonMBongABDrewniokC. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst2003; 95:1138–49.
27.
SchonMPSchonM. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis2004; 9:291–8.
28.
VenderRBGoldbergO. Innovative uses of imiquimod. J Drugs in Dermatol2005; 4:58–63.
29.
SterryWRuzickaTHerreraE. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol2002; 147:1227–36.
30.
HenggeURSchallerJ. Successful treatment of invasive squamous cell carcinoma using topical imiquimod. Arch Dermatol2004; 140:404–6.
31.
Mackenzie-WoodAKossardSde LauneyJWilkinsonBOwensML. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol2001; 44:462–70.
32.
PowellAMRussell-JonesRBarlowRJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol2004; 29:15–21.
33.
BoruckiUMetzeD. Topical treatment of lentigo maligna melanoma with imiquimod 5% cream. Dermatology2003; 207:326–8.
34.
BhatiaN. Imiquimod as a possible treatment for keratoacanthoma. J Drugs Dermatol2004; 3:7–4.
35.
DidonaBBenucciRAmerioPCanzonaFRienzoOCavalieriR. Primary cutaneous CD30 T cell lymphoma responsive to topical imiquimod (Aldara). Br J Dermatol2004; 150:1198–201.
36.
DummerRUrosevicMKempfWKazakovDBurgG. Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides. Dermatology2003; 207:116–18.
37.
ZampognaJCFlowersFPRothWIHasseneinAM. Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports. J Am Acad Dermatol2003; 47:S229–35.
38.
WolfIHSmolleJBinderB. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol2003; 139:273–6.
39.
HenggeURGoosMArndtR. Topical treatment of warts and mollusca with imiquimod. Ann Intern Med2000; 132:95.
40.
StockflethERowertJArndtRChristophersEMeyerT. Detection of human papillomavirus and response to topical 5% imiquimod in a case of stucco keratosis. Br J Dermatol2000; 143:846–50.
41.
SeebergerJDaoudSPammerJ. Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod. Int J Dermatol2003; 42:576–9.
42.
BermanBKaufmanJ. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol2002; 47:S209–11.
43.
BensonE. Imiquimod: potential risk of an immunostimulant. Australas J Dermatol2004; 45:123–4.
44.
OwensMLBridsonWESmithSLMyersJAFoxTLWellsTM. Percutaneous penetration of Aldara cream, 5% during the topical treatment of genital and perianal warts. Prim Care Update Ob Gyns1998; 5:151.
45.
HarwoodCAPerrettCMBrownVLLeighIMMcGregorJMProbyCM. Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals. Br J Dermatol2005; 152:122–9.
46.
BrownVLAtkinsCLGhaliLCerioRHarwoodCAProbyCM. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch Dermatol2005; 141:985–93.
47.
UlrichCBichelJEuvrardS. Topical immunomodulation under systemic immunosuppression: results of a multicenter, randomized, placebo controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney-, heart, and liver transplant Patients. Br J Dermatol2000; 157(S):25–31.
48.
GayedSL. Topical imiquimod cream 5% for resistant perianal warts in a renal transplant patient. Int J STD AIDS2002; 13:501–3.
49.
StockflethEMeyerTBenninghoffB. A randomized, double-blind, vehicle controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol2002; 138:1498–502.
50.
VidalDAlomarA. Efficacy of imiquimod 5% cream for basal cell carcinoma in transplant patients. Clin Exp Dermatol2004; 29:237–9.
51.
UlrichCBuschJOMeyerTNindlISchmookWSterryWStockflethE. Successful treatment of multiple actinic keratosis in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol2006; 155:451–4.
52.
Ben M'barekLMebazaaAEuvrardSFrancesCThervetEMorelPMenaschéSLegendreCLebbeC. 5% Topical imiquimod tolerance in transplant recipients. Dermatology2007; 215:130–3.
53.
SmithKJGermainMSkeltonH. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg2001; 27:561–4.
54.
PrinzBMHafnerJDummerRBurgGBruswangerUKempfW. Treatment of Bowen's disease with imiquimod 5% cream in transplant recipients. Transplantation2004; 77:790–1.
55.
WeisshaarEGollnickH. Potentiating effect of imiquimod in the treatment of verrucae vulgares in immunocompromised patients. Acta Derm Venereol2000; 80:306–7.
56.
MbulaiteyeSMEngelsEA. Kaposi's sarcoma risk among transplant recipients in the United States (1993–2003). Int J Cancer2006; 119:2685–91.
57.
BabelNEiblNUlrichCBoldGSefrinAHammerMHRosenbergerCReinkeP. Development of Kaposi's sarcoma under sirolimus based immunosuppression and successful treatment with imiquimod. Transpl Infect Dis2007; 10:59–62.
58.
BrownCWO'DonoghueMMooreJTharpM. Recalcitrant molluscum contagiosum in an HIV-afflicted male treated successfully with topical imiquimod. Cutis2000; 65:363–6.
59.
HenggeURCusiniM. Topical immunomodulators for the treatment of external genital warts, cutaneous warts and molluscum contagiosum. Br J Dermatol2003; 149(S):15–9.
60.
GardnerLSOrmondPJ. Treatment of multiple giant molluscum contagiosum in a renal transplant patient with imiquimod 5% cream. Clin Experimen Dermatol2006; 31:452–82.
